Skip to main content
Sign In

Clinical Trials

Volunteer to Be Part of a Research Study


You can search for specific diseases or conditions in our Clinical Trials list (the page takes a few seconds to load due to the quantity of trials).

Page through all School of Medicine clinical and research trials below, or click here to look for specific types of trials.
(It will take a few seconds to load) There are two categories: 

  • Detailed Trial Descriptions, submitted by researchers, includes trial specifics and contact information.

  • Additional Clinical Trials, which include basic study details. To contact the researcher either Google the PI (primary investigator) name or use our campus directory.

If you are a researcher seeking volunteers and your study is not posted, please submit your Web ad here.  

Detailed Trial Descriptions

 Results From Research and Clinical Trials : Selected site
Data pager
Page Size
 |  Displaying page 1 of 4, items 1 to 30 of 100.
COMIRB Approved Advertisement TitleStudy GoalsEligibility CriteriaDate Posted
Data pager
Page Size
 |  Displaying page 1 of 4, items 1 to 30 of 100.
Brown Adipose Tissue and Estrogen (BATE Study)
To investigate whether estrogen influences the activity of brown adipose tissue.
Healthy non-smoking women 20-40 who have regular menstrual cycles and are not on hormonal contraceptives and exercise more than once per week
Type 2 Diabetes and Exercise Research Study
Perceived exertion during exercise
Person 50-70 with or without Type 2 diabetes who exercise vigorously less than one hour per week and have normal blood pressure.  You should have a BMI between 25-35 and have not smoked for a least one year.
Is your child 6-18 years old and interested in participating in a research study?
To study the effects of polycystic kidney disease (PKD) on blood vessel function
Children 6-22 free from kidney disease and other chronic diseases
Evaluation of Glucose Sensor and Insulin Infusion Set Failures: Lipohypertrophy Study
This study is looking at evaluating Insulin Pump Infusion sites and Continuous Glucose Monitoring sites in tissue with Lipohypertrophy. We will also be looking at using the sites for a longer duration.
Lipohypertrophy site of 3 cm or greater in diameter Ages 12-45 inclusive A1C Value of < 10% Insulin pump use of at least 3 month duration Pump use with Medtronic, Animas or T-slim Willing to wear two CGM's during the 4 weeks of the study
Are you trying to lose weight?
Volunteers needed for a research study about the weight loss medication Phentermine  
Healthy and between 30-45 years of age •Have a BMI between 30 and 40 (calculate your BMI at •Willing to take the weight loss medication Phentermine for a period of 8 weeks (but not currently taking any approved or investigational medication for weight loss)
Participants Ages 12-15 years old Needed for Research Study
To learn about how children with absence epilepsy compare to healthy children in areas such as behavior, neuropsychological skills and quality of life.
Healthy hispanic individuals who are 12-15 years; No history of seizures, seizure like episodes, neurological diseases or a loss of consciousness greater than 5 minutes in their immediate family
Are you stopping your birth control because you want to become pregnant?
To look at contraception rates after birth control discontinuation.
Women 18-35 who are planning to, or have recently stopped their birth control because they want to become pregnant.
Healthy Postmenopausal Women needed to participate in a research study
To test whether estrogen has different effects on blood sugar early in menopause compared to many years after menopause​.​
Women 45-70 who have gone through menopause within the past 6 years or are more than 10 years past menopause, never used hormone therapy for more than 6 months and are willing to use estrogen patches for 1 week.  Must be a non-smoker and sedentary to moderately active.
Type 1 Diabetes Research Study
To study the effects of a medication on metabolism and blood vessel function.
Persons 25-50 years old with or without type 1 diabetes with normal blood pressure and exercise vigorously no greater than 3 times per week.
This study will look at the body's immune response (how the body fights infection) to the onset of shingles. 1-2 study visits for blood draws, over the course of 3 months.
18+ years of age; NO PRIOR HISTORY of shingles; have NEVER received the shingles vaccine; have DEVELOPED SHINGLES within the last 10 days.
Shingles Vaccine Clinical Research Trial
This study will compare responses to two shingles vaccines - the current FDA approved shingles vaccine and an investigational shingles vaccine in younger and older people.
50-59 years of age or 70-85 years of age; General good health; No prior history of shingles; Have never received the shingles vaccine; although... a subset of 70-85 year olds who DID receive the shingles vaccine at least 5 years previously is also needed (must be able to provide documentation of vaccination)
protein and infant growth: Do you have a child younger than 6 months
Participants in this research study on protein from complementary foods (meat or dairy) and infant growth, will learn how protein consumption affects your child’s growth, fat gain, and gut health from 6 to 12 months of age.  
To qualify, you child needs to be: 1. Formula fed, or not on breast-milk longer than 1 month. 2. Younger than 6 months. 3. Generally healthy. You will receive commercially available complementary foods for 7 months, Receive infant formula at no cost for 7 months, You will know your child's body fat and fat free mass and blood lipid level.
Volunteers Needed: Thinking and Memory in Parkinson's Disease
This research study aims to better understand how changes in brain activity may be related to thinking problems in Parkinson's Disease and to determine whether, by stimulating certain areas, thinking and memory can be improved.
Person's with Parkinson's Disease with mild thinking and memory problems. Between 40-90 years old. No metal in your body. No implant. Not taking any medication to improve memory. Not taking stimulants or seizure medication.
Diabetic Male and Female Volunteers Needed for Exercise Research Study
Evaluate exercise function during single leg calf exercise in people with or without type 2 diabetes
Healthy Adults 30-70 with Type 2 diabetes but not using insulin.  Must be a non-smoker who exercise no more than one time per week and have a BMI of 25-40
Trouble Controlling your Type 2 Diabetes?
Investigational non-surgical device that may help decrease blood sugar.
Adults 21-65 with type 2 Diabetes and not on oral medication, not taking insulin. Must have an A1C level of 8-10%, be overweight or obese and willing to attend study visits
To learn more about the medical marijuana industry in Colorado and its relationship to health risk behaviors and healthcare.
Persons 18+ currently a medical marijuana patient or currently using non-medical marijuana
Volunteers needed for a research study of men who are carriers of the Fragile X gene
Study the effects of the Fragile X Tremor-Ataxia Syndrome (FXTAS) on mental abilities and brain functioning.  A better understanding of FXTAS should lead to improved diagnosis, and eventually to means of treating both the symptoms and the disease.
Men age 62 or above who have a least 12 years of education and who have no neurological disorders.
Persons with active, moderate to severe ulcerative colitis needed
This study is being conducted to investigate the efficacy of methotrexate in treating ulcerative colitis in patients that have active, moderate to severe colitis and have failed other types of therapies.
Inclusion: Ages 18-70 Ulcerative colitis has been diagnoses by routine criteria At least one of the following applies: steroid dependent failed 5-ASA (mesalamine) therapy, such as Asacol Failed/lost response to infliximab (Remicade) Intolerant/unresponsive to azathioprine (Imuran) or 6-MP (purinethol) therapy Exclusion (partial): Existing pregnancy, lactation, or planned pregnancy (men and women)
3D Gait Analysis Participants Needed
Research study investigating the coordination of walking
Subject with Spastic Cerebral Palsy Inclusion Criteria: ● Males and females between the ages of 7 and 100 years of age. ● Retrospective gait data must contain a complete lower body marker set and valid kinetic data. ● Only gait data trials of the subject walking unassisted will be used. ● Diagnosis of spastic cerebral palsy. ● Exhibits either stiff knee gait pattern, characterized by insufficient and delayed peak knee flexion during swing (less than 45), or crouch gait pattern, characterized by excessive hip flexion and knee flexion (greater than 30 throughout stance). Cerebellar Ataxic Gait Subject Inclusion Criteria: ● Males and females between the ages of 7 and 100 years of age. ● Ability to walk continuously and unassisted for 3 minutes. ● If under the age of 18, parent consent and subject assent. ● Diagnosis of either Friedreich's or spinocerebellar ataxia. Subject with Lower Limb Amputation Inclusion Criteria: ● Males and females between the ages of 7 and 100 years of age. ● Ability to walk continuously and unassisted for 3 minutes. ● If under the age of 18, parent consent and subject assent. ● Has been using the prosthetic limb for at least 6 months for independent ambulation prior to gait analysis at CGMA. ● Below knee or above knee amputation.
Be Influential - Influenza Study
Doctors at the National Institutes of Health are conducting a research study (IRC-003) to investigate whether treating the influenza virus (flu) with a combination of drugs is better than the standard therapy with one drug.
Volunteers may be male or female and must: -be at least 18 years old -have a history of an influenza-like illness (typically this would consist of a fever, cough, and aches) -have an onset of illness within the past 96 hours -have a medical condition(s) that has been associated with increased risk of complications from influenza
Would you like to participate in a study to improve the understanding of how emotions and symptom distress affect adherence to hormonal therapy in breast cancer?
The purpose of this study is to understand how emotional factors and symptom distress affect adherence to hormonal therapy in women that have completed all other treatment for breast cancer.   
Women Breast Cancer Survivor Age 21-70 years old Within 24 months of starting hormonal therapy: Aromatase Inhibitors or Tamoxifen (Aromatase Inhibitors, Exemestane (aromasin), Letrolzole (Femara), Anastrozole (Arimidex).
Do you spend most of your day sitting?
The Anschutz Health & Wellness Center is seeking participants for a new research project to determine if exercise performed throughout the day is more energizing compared to exercise performed in the morning or if you do not exercise.
Participants must meet the following criteria: - Sedentary - Between the ages of 25 - 50 - BMI between 18.5 and 29.9 kg/m^2 - Non-smoker
Help Us Learn About Schizophrenia!
Help us learn more about a new drug that may improve thinking and concentration in people with schizophrenia.
We are looking for: Male and female adults who smoke 18-50 years old No previous or current mental illness No drug use Willing to use nicotine patch during study hospital visit If female, willing to use birth control during the study
Women needed for Research Study
To examine how BMI affects fertility
Healthy women 18-39 with a BMI greater than 30 with regular menstrual cycles and not pregnant or trying to conceive and not on any hormones (like birth control).  Must be willing to collect your first morning urine daily for one menstrual cycle and provide blood samples.
Are you taking medications for diabetes and resulting kidney complications?
To evaluate a new investigational drug for people with Type 2 diabetes and kidney disease.
Person 18+ who are not of child bearing potential (f female) with type 2 diabetes and currently taking medication for kidney disease. You must be able to attend at least 6 office visits over 16 weeks.
Apoyo con Cariño: Improving Palliative Care for Latinos with Cancer
We want to understand if a patient navigator can help Latino patients and their family caregivers deal with cancer. Our project hopes to improve palliative or comfort care to patients with advanced cancer. The goal is to prevent or relieve suffering for people facing serious illness. Research is needed to find out if a patient navigator can help patients and family caregivers.
Adults (18 years and older) who self-identify as Latino and have Stage III-IV cancer.
Seeking Adults with NO History of Eczema, Allergies or Asthma
The purpose of this study is to determine why some individuals with atopic dermatitis are at increased risk for skin infections.
Males and females between 18 and 64years of age with no history of Allergies, Eczema, or Asthma
SPIROMICS-Subpopulations and Intermediate Outcome Measures in COPD Study
To identify subpopulations of COPD patients in order to develop newer and more effective treatments and to clearly define measureable end points so that treatment effects may be accurately assessed in a shorter period of time.
Be willing to undergo study procedures Be between the age of 40 and 80 years old Have smoked fewer than one pack of cigarettes per day for one year OR have smoked more than one pack of cigarettes per day for 20 years
Psychiatric Medication Study
We are looking for volunteers to participate in a research study investigating how psychiatric medications are processed in people who are diagnosed with HIV-1 compared to subjects who are on psychiatric medications who are HIV-negative. You can participate in this study if you are HIV negative and taking certain psychiatric medications.
To Qualify: Must between the ages of  2 to <25 years; Be HIV-Negative; On a steady dose of Psychiatric Medication (Celexa, Lexapro, Risperdal, Zoloft, Prozac, Paxil or generic equivalents)
HEALTHY MEN AND WOMEN 60-85 YEARS OLD Wanted to participate in a research study
To test whether interrupting prolonged sitting with short bouts of moderate intensity walking can improve health
We are looking for men and women who:  Are age 60-85 years old  Healthy – no diagnosed disease  Not on glucose lowering medication  Do not participate in regular exercise  Ambulatory – able to walk without assistance  Are non-smokers

​Additional Clinical Trails

 Results From Research : Selected site
Data pager
Page Size
 |  Displaying page 1 of 16, items 1 to 30 of 451.
Protocol TitlePI NameInstitution Number
Data pager
Page Size
 |  Displaying page 1 of 16, items 1 to 30 of 451.
Eisenmenger Quality Enhancement Research Initiative (QuERI). Sponsor Protocol 20111728. WIRB Protocol No. 20111728
Kay, Joseph12-0926
A Single-arm Study to Assess the Efficacy and Safety of Oral Rigosertib in Transfusion-dependent, Low or Intermediate-1, Myelodysplastic Syndrome Patients Based on the International Prognostic Scoring System. Sponsor Protocol # 09-07. WIRB Protocol # 20131128
Pollyea, Daniel13-2064
A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study Evaluating Two Doses of Subcutaneous Pulsatile GnRH Administered via OmniPod Pump for Ovulation Induction in Female Subjects with Primary Amenorrhea with Hypogonadotropic Hypogonadism. Sponsor Protocol No. 000070. WIRB Protocol No. 20140452
Santoro, Nanette13-2352
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Phase 3 Study of the Safety, Tolerability, and Efficacy of CMX001 for the Prevention of Cytomegalovirus (CMV) Infection in CMV-seropositive (R+) Hematopoietic Stem Cell Transplant Recipients. Sponsor Protocol No. CMX001-301. WIRB Protocol No. 20131501
Gutman, Jonathan13-2441
A Phase 2 Study of ABT-199 in Subjects with Acute Myelogenous Leukemia (AML). Sponsor Protocol No. M14-212. WIRB Protocol No. 20131839
Pollyea, Daniel13-2463
A Phase 1b, multi-center, two parallel group, open-label, drug-drug interaction study to assess the effect of LDE225 on the pharmacokinetics of bupropion and warfarin in patients with advanced solid tumors. Sponsor Protocol No. CLDE225A2112. WIRB Protocol No.20130681
Lewis, Karl13-2556
A Phase 1 Dose-Escalation Study of LY2940680 in Patients with Advanced Cancer. Sponsor Protocol No. I4J-MC-HHBB(e). WIRB Protocol No. 20101374
Lewis, Karl13-2557
A Multicenter, Randomized, Controlled, Three-Arm, Phase III Study to Evaluate the Safety and Efficacy of Two Dosing Schedules of MK-3475 Compared to Ipilimumab Patients with Advanced Melanoma. Sponsor Protocol No. 006. WIRB Protocol No. 20130483
Gonzalez, Rene13-2581
Phase I Study of Platinum-based Chemoradiotherapy (CRT) with Oral Rigosertib in Patients with Intermediate or High-risk Head and Neck Squamous Cell Carcinoma. Sponsor Protocol No. 09-12. WIRB Protocol No. 20132209
Jimeno, Antonio13-2591
A Multicenter, Double Blind, Randomized, Placebo-Controlled Trial to Determine the Efficacy and Safety of Ganaxolone as Adjunctive Therapy for Adults with Drug-Resistant Partial-Onset Seizures Followed by Long-term Open-Label Treatment. Sponsor Protocol No. 1042-0603. WIRB Protocol No. 20131531
Strom, Laura13-2603
A Phase 1 Dose Escalation Study of OMP-52M51 in Subjects with Lymphoid Malignancies. Sponsor Protocol No. 52M51-001. WIRB Protocol No. 20121889
Gore, Lia13-2642
A Phase III, Double-Blind, Randomised, Placebo-Controlled Study to Assess the Efficacy and Safety of Selumetinib (AZD6244; ARRY-142886)(Hyd-Sulfate) in Combination with Docetaxel, in Patients receiving second line treatment for KRAS Mutation-Positive Locally Advanced or Metastatic Non Small Cell Lung Cancer (Stage IIIB – IV) (SELECT-1). Sponsor Protocol No. D1532C00079. WIRB Protocol No. 20131837
Oton, Ana13-2647
A Randomized Phase 2 Study of Oral AP26113 in Patients with ALK-positive, Non-small Cell Lung Cancer (NSCLC) Previously Been Treated with Crizotinib. Sponsor Protocol No. AP26113-13-201. WIRB Protocol No.20131562
Camidge, David13-2648
Gore, Lia13-2649
A 12-Week Multicenter, Randomized, Double-Blind,Placebo-Controlled Study Comparing the Efficacy and Safety of LY2439821 to Etanercept and Placebo in Patients with Moderate to Severe Plaque Psoriasis with a Long-Term Extension Period. Sponsor Protocol No. I1F-MC-RHBC(b). WIRB Protocol No. 20121432
Armstrong, April13-2723
Lam, Elaine13-2806
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Efficacy and Safety of Enzalutamide in Combination With Exemestane in Patients With Advanced Breast Cancer That Is Estrogen or Progesterone Receptor-Positive and HER2-Normal. Sponsor Protocol No. MDV3100-12. WIRB Protocol No. 20131280
Elias, Anthony13-2892
A Randomized, Double-Blind, Placebo-Controlled Study of Chemotherapy Plus Cetuximab in Combination with VTX-2337 in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck. Sponsor Protocol No. VRXP-A202. WIRB Protocol No. 20131627
Jimeno, Antonio13-2911
A Randomized, Global, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Once-daily Oral Avatrombopag for the Treatment of Adults with Thrombocytopenia Associated with Liver Disease Prior to an Elective Procedure. Sponsor Protocol No. E5501-G000-311. WIRB Protocol No. 20131907
Everson, Greg13-2914
A 24 month, multicenter, randomized, open-label safety and efficacy study of concentration-controlled everolimus with reduced calcinerurin inhibitor vs mycophenolate with standard calcineurin inhibitor in de novo renal transplantation- Advancing renal TRANSplant eFficacy and safety Outcomes with an eveRolimus-based regiMen (TRANSFORM). Sponsor Protocol No. CRAD001A2433. WIRB Protocol No. 20140590
Wiseman, Alexander13-2918
A Multicenter, Randomized, Open-Label, Phase 2 Study of Carfilzomib With or Without ARRY-520 in Patients with Advanced Multiple Myeloma. Sponsor Protocol No. ARRAY-520-216. WIRB Protocol No. 20131633
Smith, Clayton13-2932
PROSPER: A Multinational, Phase 3, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Enzalutamide in Patients with Nonmetastatic Castration-Resistant Prostate Cancer. Sponsor Protocol No. MDV3100-14. WIRB Protocol No. 20131112
Crawford, E13-2937
A Phase III Randomized, Double-Blind, Placebo-Controlled, Multicentre Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed BRCA Mutated Ovarian Cancer Patients who are in Complete or Partial Response Following Platinum based Chemotherapy. Sponsor Protocol No. D0816C00002. WIRB Protocol No. 20131789
Davidson, Susan13-2969
A Phase 1b/2 Study of Safety and Efficacy of MLN0128 (Dual TORC1/2 Inhibitor) in Combination With Exemestane or Fulvestrant Therapy in Postmenopausal Women With ER+/HER2- Advanced or Metastatic Breast Cancer That Has Progressed on Treatment With Everolimus in Combination With Exemestane or Fulvestrant. Sponsor Protocol No. C31001. WIRB Protocol No. 20132212
Diamond, Jennifer13-2999
A Phase 1b, open-label study to assess the safety and tolerability of ONT-380 combined with capecitabine and trastuzumab, alone and in combination in HER2+ metastatic breast cancer. Sponsor Protocol No. ONT-380-005. WIRB Protocol No. 20140127
Borges, Virginia13-3000
A Randomized Phase 2 Study of Cabozantinib (XL184) in Combination with Abiraterone in Chemotherapy Naïve Subjects with Bone-Metastatic Castration-Resistant Prostate Cancer. Sponsor Protocol No. XL184-210. WIRB Protocol No. 20140076
Flaig, Thomas13-3004
A Phase II, Multicenter, Randomized, Observer-Blind, Controlled Study to Evaluate Safety and Immunogenicity of a Trivalent Group B Streptococcus Vaccine in Healthy Pregnant Women. Sponsor Protocol No. V98_12. WIRB Protocol No. 20140324
Gibbs, Ronald13-3019
GORE® HELEX® Septal Occluder/GORE® Septal Occluder and Antiplatelet Medical Management for Reduction of Recurrent Stroke or Imaging-Confirmed TIA in Patients with Patent Foramen Ovale (PFO). Sponsor Protocol No. HLX 06-03. WIRB Protocol No. 20080907
Kim, Michael13-3034
A Prospective, Randomized, Controlled, Unblinded, Multi-Center Clinical Trial to Evaluate the HeartWare® Ventricular Assist Device System for Destination Therapy of Advanced Heart Failure. Sponsor Protocol No. HW004-A. WIRB Protocol No. 20131526
Cleveland, Joseph13-3039
A Phase 3 Open-Label Study to Evaluate Switching from Optimized Stable Antiretroviral Regimens Containing Darunavir to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Single Tablet Regimen (STR) plus Darunavir (DRV) in Treatment Experienced HIV-1 Positive Adults. Sponsor Protocol No. GS-US-292-0119. WIRB Protocol No. 20131690
Campbell, Thomas13-3072